Report Information More information from: https ://www.wis eguyreports .com/reports /495861
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2016 Report / Search Code: WGR495861
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Pipeline Review, H1 2016’, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia), complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - The report reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) therapeutics and enlis ts all their major and minor projects - The report as s es s es Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under
development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Introduction 7 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Overview 8 Therapeutics Development 9 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Therapeutics under Development by Companies 11 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Therapeutics under Inves tigation by Univers ities /Ins titutes 18 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Pipeline Products Glance 20 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Products under Development by Companies 23 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Products under Inves tigation by Univers ities /Ins titutes 33 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Companies Involved in Therapeutics Development 35 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Therapeutics As s es s ment 116 Drug Profiles 135 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Recent Pipeline Updates 456 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Dormant Projects 693 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Dis continued Products 699 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Product Development Miles tones 701 Appendix 710 Lis t of Tables Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia), H1 2016 28 Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Comparative Analys is , H1 2016 29 Number of Products under Development by Companies , H1 2016 30 Number of Products under Development by Companies , H1 2016 (Contd..1) 31 Number of Products under Development by Companies , H1 2016 (Contd..2) 32 Number of Products under Development by Companies , H1 2016 (Contd..3) 33 Number of Products under Development by Companies , H1 2016 (Contd..4) 34 Number of Products under Development by Companies , H1 2016 (Contd..5) 35 Number of Products under Development by Companies , H1 2016 (Contd..6) 36 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 38 Comparative Analys is by Late Stage Development, H1 2016 39 Comparative Analys is by Clinical Stage Development, H1 2016 40 Comparative Analys is by Early Stage Development, H1 2016 41 Products under Development by Companies , H1 2016 42 Products under Development by Companies , H1 2016 (Contd..1) 43 Products under Development by Companies , H1 2016 (Contd..2) 44 Products under Development by Companies , H1 2016 (Contd..3) 45 Products under Development by Companies , H1 2016 (Contd..4) 46 Products under Development by Companies , H1 2016 (Contd..5) 47 Products under Development by Companies , H1 2016 (Contd..6) 48 Products under Development by Companies , H1 2016 (Contd..7) 49 Products under Development by Companies , H1 2016 (Contd..8) 50 Products under Development by Companies , H1 2016 (Contd..9) 51 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 52 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 (Contd..1) 53 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Pipeline by 4SC AG, H1 2016 54 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Pipeline by AbbVie Inc., H1 2016 55 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Pipeline by
Actinium Pharmaceuticals , Inc., H1 2016 56 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Therapeutics Sarl, H1 2016 57 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Affimed Therapeutics AG, H1 2016 58 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) BioScience Corporation, H1 2016 59 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Amgen Inc., H1 2016 60 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Pharmaceuticals , Inc., H1 2016 61 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) BioPharma Inc., H1 2016 62 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) As traZ eneca Plc, H1 2016 63 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Biotherapeutics , Inc., H1 2016 64 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Baxalta Incorporated, H1 2016 65 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Bellicum Pharmaceuticals , Inc., H1 2016 66 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Bexion Pharmaceuticals , LLC., H1 2016 67 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Path Holdings , Inc., H1 2016 68 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) BioSight Ltd., H1 2016 69 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Bris tol-Myers Squibb Company, H1 2016 70 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Calithera Bios ciences , Inc., H1 2016 71 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Celator Pharmaceuticals , Inc., H1 2016 72 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Celgene Corporation, H1 2016 73 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Cellectis S.A., H1 2016 74 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Cellular Biomedicine Group, Inc., H1 2016 75 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Ceronco Bios ciences , H1 2016 76 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Cons tellation Pharmaceuticals , Inc., H1 2016 77 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Cyclacel Pharmaceuticals , Inc., H1 2016 78 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Daiichi Sankyo Company, Limited, H1 2016 79 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) DiNonA Inc., H1 2016 80 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Effimune S.A., H1 2016 81 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Lilly and Company, H1 2016 82 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) EpiZ yme, Inc., H1 2016 83 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Erytech Pharma SA, H1 2016 84 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Eureka Therapeutics , Inc., H1 2016 85 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Formula Pharmaceuticals , Inc., H1 2016 86 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Gamida Cell Ltd., H1 2016 87 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) GlaxoSmithKline Plc, H1 2016 88 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Hangzhou Mins heng Pharmaceutical Group Co.,Ltd, H1 2016 89 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) biotech SAS, H1 2016 90 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Immunomedics , Inc., H1 2016 91 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Incyte Corporation, H1 2016 92 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Interprotein Corporation, H1 2016 93 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Pharmaceuticals , LLC., H1 2016 94 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia)
- Pipeline by ADC - Pipeline by - Pipeline by Altor - Pipeline by - Pipeline by Ariad - Pipeline by Array - Pipeline by - Pipeline by Atara - Pipeline by - Pipeline by - Pipeline by - Pipeline by Bio- Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by Eli - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by iDD - Pipeline by - Pipeline by - Pipeline by - Pipeline by Jas co - Pipeline by
Johns on & Johns on, H1 2016 95 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Therapeutics Inc., H1 2016 96 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) KaloBios Pharmaceuticals , Inc., H1 2016 97 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Karyopharm Therapeutics , Inc., H1 2016 98 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Kiadis Pharma B.V., H1 2016 99 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Pharma, Inc., H1 2016 100 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) medac GmbH, H1 2016 101 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Merck & Co., Inc., H1 2016 102 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Therapeutics , Inc., H1 2016 103 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Nanovalent Pharmaceuticals Inc., H1 2016 104 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) NantKwes t, Inc., H1 2016 105 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Novartis AG, H1 2016 106 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) NovImmune SA, H1 2016 107 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) NuCana BioMed Limited, H1 2016 108 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Omeros Corporation, H1 2016 109 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Oncternal Therapeutics , Inc., H1 2016 110 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Oribas e Pharma, H1 2016 111 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Pfenex Inc., H1 2016 112 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Inc., H1 2016 113 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Pharma Mar, S.A., H1 2016 114 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Polyphor Ltd., H1 2016 115 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Portola Pharmaceuticals , Inc., H1 2016 116 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Quimatryx, S.L., H1 2016 117 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Pharmaceuticals , LLC, H1 2016 118 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Sanofi, H1 2016 119 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Sareum Holdings Plc, H1 2016 120 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Seattle Genetics , Inc., H1 2016 121 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Sellas Inc., H1 2016 122 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Sorrento Therapeutics , Inc., H1 2016 123 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Spectrum Pharmaceuticals , Inc., H1 2016 124 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Stemline Therapeutics , Inc., H1 2016 125 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Syros Pharmaceuticals , Inc., H1 2016 126 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Takeda Pharmaceutical Company Limited, H1 2016 127 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) TetraLogic Pharmaceuticals , H1 2016 128 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Theravectys SA, H1 2016 129 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Thres hold Pharmaceuticals , Inc., H1 2016 130 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Tolero Pharmaceuticals , Inc., H1 2016 131 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Tragara Pharmaceuticals , Inc., H1 2016 132 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Veras tem, Inc., H1 2016 133 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia)
- Pipeline by Juno - Pipeline by - Pipeline by - Pipeline by - Pipeline by Kite - Pipeline by - Pipeline by - Pipeline by Mirna - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by Pfizer - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by Red5 - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by - Pipeline by
Xbrane Biopharma AB, H1 2016 134 As s es s ment by Monotherapy Products , H1 2016 135 As s es s ment by Combination Products , H1 2016 136 Number of Products by Stage and Target, H1 2016 138 Number of Products by Stage and Mechanis m of Action, H1 2016 145 Number of Products by Stage and Route of Adminis tration, H1 2016 151 Number of Products by Stage and Molecule Type, H1 2016 153 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) Therapeutics Recent Pipeline Updates , H1 2016 475 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Dormant Projects , H1 2016 712 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Dormant Projects (Contd..1), H1 2016 713 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Dormant Projects (Contd..2), H1 2016 714 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Dormant Projects (Contd..3), H1 2016 715 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Dormant Projects (Contd..4), H1 2016 716 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Dormant Projects (Contd..5), H1 2016 717 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Dis continued Products , H1 2016 718 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Dis continued Products (Contd..1), H1 2016 719 Lis t of Figures Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia), H1 2016 28 Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblas tic Leukemia) - Comparative Analys is , H1 2016 29 Number of Products under Development by Companies , H1 2016 30 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 37 Comparative Analys is by Late Stage Development, H1 2016 39 Comparative Analys is by Clinical Stage Development, H1 2016 40 Comparative Analys is by Early Stage Products , H1 2016 41 As s es s ment by Monotherapy Products , H1 2016 135 As s es s ment by Combination Products , H1 2016 136 Number of Products by Top 10 Targets , H1 2016 137 Number of Products by Stage and Top 10 Targets , H1 2016 137 Number of Products by Top 10 Mechanis m of Actions , H1 2016 144 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 144 Number of Products by Routes of Adminis tration, H1 2016 150 Number of Products by Stage and Routes of Adminis tration, H1 2016 150 Number of Products by Top 10 Molecule Types , H1 2016 152 Number of Products by Stage and Top 10 Molecule Types , H1 2016 152
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349